Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
2.880
+0.370 (14.74%)
Jan 6, 2025, 4:00 PM EST - Market closed
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focuses on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers.
It is developing SkinJect with an indication for basal cell carcinoma. The company is headquartered in Toronto, Canada.
Medicus Pharma Ltd.
| Country | Canada |
| Founded | 2008 |
| Industry | Other |
| CEO | Raza Bokhari |
Contact Details
Address: One First Canadian Place, Suite 3400 Toronto, ON M5X 1A4 Canada | |
| Phone | 610-636-0184 |
| Website | medicuspharma.com |
Stock Details
| Ticker Symbol | MDCX |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001997296 |
| ISIN Number | CA58471K2020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Raza Bokhari | Chief Executive Officer |
| James Quinlan | Chief Financial Officer |
| Viktoriia Slepeniuk | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | 424B3 | Prospectus |
| Dec 26, 2024 | 6-K | Report of foreign issuer |
| Dec 12, 2024 | 6-K | Report of foreign issuer |
| Dec 2, 2024 | 6-K | Report of foreign issuer |
| Nov 25, 2024 | 424B3 | Prospectus |
| Nov 25, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 424B4 | Prospectus |
| Nov 14, 2024 | CERT | Certification by an exchange approving securities for listing |